RxDoctor Payments DataLook up a doctor →

Todd Antin, MD

Psychiatry · Decatur, GANPI 1598714073

Payments from drug & device makers

$1,191,476in general payments, 2019–2025

Across 2,071 payments — averaging $575.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$449K
  • Livanova USA, Inc.$164K
  • Otsuka America Pharmaceutical, Inc.$100K
  • Neurocrine Biosciences, Inc.$92K
  • Avanir Pharmaceuticals, Inc.$81K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$77K
  • plus $227K from 37 others

What the payments were for

  • Consulting fees$87,3489%
  • Speaking & faculty fees$831,74582%
  • Travel & lodging$63,9196%
  • Food & beverage$35,8174%
  • Education$3110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,191,476 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$123,050
Medicare patients
197
Services billed
1,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$116,137
TrintellixVortioxetine Hydrobromide15$7,268
Lisdexamfetamine Dimesylate13$3,952
Aripiprazole34$3,598
Divalproex Sodium ErDivalproex Sodium12$1,725
Levetiracetam15$962
Methylphenidate Hcl Er (Cd)Methylphenidate Hcl11$824
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$658
Methylphenidate ErMethylphenidate Hcl21$593
Haloperidol Decanoate11$582
Olanzapine18$567
Quetiapine Fumarate33$529
Fluoxetine Hcl19$316
Benztropine Mesylate14$233
Mirtazapine18$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$91,715$116,13714 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$5,020$7,26815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →